Keymed Biosciences Inc. (HKG:2162)
Hong Kong
· Delayed Price · Currency is HKD 46.25
-1.95 (-4.05%)
Jun 27, 2025, 4:08 PM HKT
Keymed Biosciences Revenue
In the year 2024, Keymed Biosciences had annual revenue of 428.12M CNY with 20.91% growth. Keymed Biosciences had revenue of 373.44M in the half year ending December 31, 2024, with 592,665.08% growth.
Revenue
428.12M CNY
Revenue Growth
+20.91%
P/S Ratio
29.91
Revenue / Employee
340.32K CNY
Employees
1,258
Market Cap
13.63B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| Innovent Biologics | 10.03B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| Sino Biopharmaceutical | 30.72B |
| CSPC Pharmaceutical Group | 28.99B |
| Akeso | 2.26B |